Upgrade to SI Premium - Free Trial

Doximity Announces Fourth Quarter and Fiscal Year 2024 Financial Results

May 16, 2024 4:01 PM

Fiscal year 2024 total revenues of $475.4 million, up 13% year-over-year

Fiscal year 2024 net income growth of 31% and adjusted EBITDA growth of 25% year-over-year

Q4 total revenues of $118.1 million, up 6% year-over-year

Q4 net income growth of 32% and adjusted EBITDA growth of 15% year-over-year

SAN FRANCISCO--(BUSINESS WIRE)-- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2024 fourth quarter and fiscal year ended March 31, 2024.

“We were pleased to beat on our top and bottom lines, as we delivered another quarter of strong profits and record engagement,” said Jeff Tangney, co-founder and CEO of Doximity. “We’re proud to bring AI and automation to clinical workflows, with over 580,000 unique providers using our workflow tools last quarter.”

Fiscal 2024 Fourth Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended March 31, 2023.

Fiscal Year 2024 Financial Highlights

All comparisons, unless otherwise noted, are to the fiscal year ended March 31, 2023.

Financial Outlook

Doximity is providing guidance for its fiscal first quarter ending June 30, 2024 as follows:

Doximity is providing guidance for its fiscal year ending March 31, 2025 as follows:

Stock Repurchase Program

On May 1, 2024 the Company’s board of directors authorized a program to repurchase up to $500 million of the Company’s Class A common stock. The repurchase program has no expiration date and is subject to general business and market conditions and other investment opportunities, through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans. Immediately upon the repurchase of any shares of Class A common stock, such shares shall be retired by the Company and shall automatically return to the status of authorized but unissued shares of Class A common stock. All prior repurchase programs were completed as of April 2024.

Conference Call Information

Doximity posted prepared remarks on its investor relations website at https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company’s Investor Relations page shortly after the call.

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

Forward-Looking Statements

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of uncertainty in the current economic environment and macroeconomic uncertainty; (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members’ interests; (vi) breaches in our security measures or unauthorized access to members’ data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled “Risk Factors” in the Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023. Additional information will be provided in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

DOXIMITY, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

March 31, 2024

March 31, 2023

Assets

Current assets:

Cash and cash equivalents

$

96,785

$

158,027

Marketable securities

666,115

682,972

Accounts receivable, net

101,332

107,047

Prepaid expenses and other current assets

48,709

27,407

Total current assets

912,941

975,453

Property and equipment, net

12,318

11,279

Deferred income tax assets

45,068

34,907

Operating lease right-of-use assets

12,332

13,819

Intangible assets, net

27,317

31,836

Goodwill

67,940

67,940

Other assets

1,458

1,654

Total assets

$

1,079,374

$

1,136,888

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

2,253

$

1,272

Accrued expenses and other current liabilities

43,703

31,245

Deferred revenue, current

99,145

105,238

Operating lease liabilities, current

2,149

1,752

Total current liabilities

147,250

139,507

Deferred revenue, non-current

211

198

Operating lease liabilities, non-current

12,397

13,885

Contingent earn-out consideration liability, non-current

10,895

15,942

Other liabilities, non-current

7,224

1,240

Total liabilities

177,977

170,772

Stockholders' Equity

Preferred stock

Common stock

187

194

Additional paid-in capital

823,885

762,150

Accumulated other comprehensive loss

(2,664

)

(14,083

)

Retained earnings

79,989

217,855

Total stockholders' equity

901,397

966,116

Total liabilities and stockholders’ equity

$

1,079,374

$

1,136,888

DOXIMITY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

Three Months Ended
March 31,

Fiscal Year Ended
March 31,

2024

2023

2024

2023

Revenue

$

118,057

$

110,966

$

475,422

$

419,052

Cost of revenue(1)

12,567

13,677

50,669

53,490

Gross profit

105,490

97,289

424,753

365,562

Operating expenses(1):

Research and development

20,148

21,541

81,983

80,186

Sales and marketing

33,517

33,148

133,129

123,523

General and administrative

9,973

9,759

37,827

36,745

Restructuring

7,936

Total operating expenses

63,638

64,448

260,875

240,454

Income from operations

41,852

32,841

163,878

125,108

Other income, net

6,101

3,875

21,324

8,048

Income before income taxes

47,953

36,716

185,202

133,156

Provision for income taxes

7,335

6,048

37,620

20,338

Net income

$

40,618

$

30,668

$

147,582

$

112,818

Net income per share attributable to Class A and Class B common stockholders:

Basic

$

0.22

$

0.16

$

0.78

$

0.58

Diluted

$

0.20

$

0.14

$

0.72

$

0.53

Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

Basic

186,756

193,829

190,172

193,176

Diluted

201,110

212,742

205,734

213,425

(1) Costs and expenses include stock-based compensation expense as follows (in thousands):

Three Months Ended
March 31,

Fiscal Year Ended
March 31,

2024

2023

2024

2023

Cost of revenue

$

2,274

$

2,425

$

9,479

$

9,634

Research and development

3,104

3,167

11,978

12,583

Sales and marketing

4,105

5,027

16,857

16,939

General and administrative

2,374

2,372

9,116

8,678

Restructuring

3,646

Total stock-based compensation expense

$

11,857

$

12,991

$

51,076

$

47,834

DOXIMITY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

Three Months Ended
March 31,

Fiscal Year Ended
March 31,

2024

2023

2024

2023

Cash flows from operating activities

Net income

$

40,618

$

30,668

$

147,582

$

112,818

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

2,548

2,708

10,265

10,283

Deferred income taxes

(8,593

)

3,834

(8,593

)

13,226

Stock-based compensation, net of amounts capitalized

11,857

12,991

51,076

47,834

Non-cash lease expense

475

537

2,074

2,027

Amortization of premium (accretion of discount) on marketable securities, net

(1,761

)

(29

)

(5,238

)

3,115

Net loss on sale of marketable securities

402

1,093

Amortization of deferred contract costs

2,593

2,428

8,871

8,785

Change in fair value of contingent earn-out consideration liability

183

405

951

728

Other

773

252

1,230

726

Changes in operating assets and liabilities, net of effect of acquisition:

Accounts receivable

(4,516

)

(32,433

)

3,993

(26,242

)

Prepaid expenses and other assets

(16,502

)

(5,372

)

(20,483

)

(3,448

)

Deferred contract costs

(1,683

)

(2,053

)

(8,608

)

(8,462

)

Accounts payable, accrued expenses and other liabilities

5,966

(2,918

)

8,332

(195

)

Deferred revenue

32,496

35,625

(6,080

)

17,527

Operating lease liabilities

(510

)

(4

)

(1,678

)

(213

)

Net cash provided by operating activities

63,944

46,639

184,096

179,602

Cash flows from investing activities

Cash paid for acquisition

(53,500

)

Purchases of property and equipment

(21

)

(147

)

(1,701

)

Internal-use software development costs

(1,634

)

(1,005

)

(5,654

)

(4,483

)

Purchases of marketable securities

(191,529

)

(60,303

)

(472,867

)

(190,560

)

Maturities of marketable securities

116,993

48,125

435,179

83,139

Sales of marketable securities

74,675

107,182

Net cash provided by (used in) investing activities

(76,170

)

(13,204

)

31,186

(59,923

)

Cash flows from financing activities

Proceeds from issuance of common stock upon exercise of stock options and common stock warrants

3,134

2,471

12,892

9,926

Proceeds from issuance of common stock in connection with the employee stock purchase plan

1,952

2,418

3,446

4,759

Taxes paid related to net share settlement of equity awards

(1,424

)

(1,469

)

(6,756

)

(3,822

)

Repurchase of common stock

(17,740

)

(15,282

)

(280,716

)

(85,324

)

Payment of contingent consideration related to a business combination

(5,390

)

Net cash used in financing activities

(14,078

)

(11,862

)

(276,524

)

(74,461

)

Net increase (decrease) in cash and cash equivalents

(26,304

)

21,573

(61,242

)

45,218

Cash and cash equivalents, beginning of period

123,089

136,454

158,027

112,809

Cash and cash equivalents, end of period

$

96,785

$

158,027

$

96,785

$

158,027

Supplemental disclosures of cash flow information

Cash paid for taxes, net of refunds

$

12,911

$

2,727

$

51,274

$

5,231

Non-GAAP Financial Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:

We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Business Metrics

Reconciliation of GAAP to Non-GAAP Financial Measures

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Three Months Ended
March 31,

Fiscal Year Ended
March 31,

2024

2023

2024

2023

(unaudited)

(in thousands, except percentages)

Net income

$

40,618

$

30,668

$

147,582

$

112,818

Adjusted to exclude the following:

Acquisition and other related expenses

30

Stock-based compensation

11,857

12,991

47,430

47,834

Depreciation and amortization

2,548

2,708

10,265

10,283

Provision for income taxes

7,335

6,048

37,620

20,338

Restructuring expense

7,936

Change in fair value of contingent earn-out consideration liability

183

405

951

728

Other income, net

(6,101

)

(3,875

)

(21,324

)

(8,048

)

Adjusted EBITDA

$

56,440

$

48,945

$

230,460

$

183,983

Revenue

$

118,057

$

110,966

$

475,422

$

419,052

Net income margin

34.4

%

27.6

%

31.0

%

26.9

%

Adjusted EBITDA margin

47.8

%

44.1

%

48.5

%

43.9

%

Three Months Ended
March 31,

Fiscal Year Ended
March 31,

2024

2023

2024

2023

(unaudited)

(in thousands)

Net cash provided by operating activities

$

63,944

$

46,639

$

184,096

$

179,602

Purchases of property and equipment

(21

)

(147

)

(1,701

)

Internal-use software development costs

(1,634

)

(1,005

)

(5,654

)

(4,483

)

Free cash flow

$

62,310

$

45,613

$

178,295

$

173,418

Other cash flow components:

Net cash provided by (used in) investing activities

$

(76,170

)

$

(13,204

)

$

31,186

$

(59,923

)

Net cash used in financing activities

$

(14,078

)

$

(11,862

)

$

(276,524

)

$

(74,461

)

Three Months Ended
March 31,

Fiscal Year Ended
March 31,

2024

2023

2024

2023

(unaudited)

(in thousands, except per share data and percentages)

GAAP cost of revenue

$

12,567

$

13,677

$

50,669

$

53,490

Adjusted to exclude the following:

Stock-based compensation

(2,274

)

(2,425

)

(9,479

)

(9,634

)

Amortization of acquired intangibles

(137

)

(274

)

(548

)

Non-GAAP cost of revenue

$

10,293

$

11,115

$

40,916

$

43,308

GAAP gross profit

$

105,490

$

97,289

$

424,753

$

365,562

Adjusted to exclude the following:

Stock-based compensation

2,274

2,425

9,479

9,634

Amortization of acquired intangibles

137

274

548

Non-GAAP gross profit

$

107,764

$

99,851

$

434,506

$

375,744

GAAP gross margin

89.4

%

87.7

%

89.3

%

87.2

%

Non-GAAP gross margin

91.3

%

90.0

%

91.4

%

89.7

%

GAAP research and development expense

$

20,148

$

21,541

$

81,983

$

80,186

Adjusted to exclude the following:

Stock-based compensation

(3,104

)

(3,167

)

(11,978

)

(12,583

)

Non-GAAP research and development expense

$

17,044

$

18,374

$

70,005

$

67,603

GAAP sales and marketing expense

$

33,517

$

33,148

$

133,129

$

123,523

Adjusted to exclude the following:

Stock-based compensation

(4,105

)

(5,027

)

(16,857

)

(16,939

)

Amortization of acquired intangibles

(1,061

)

(979

)

(4,244

)

(4,164

)

Change in fair value of contingent earn-out consideration liability

(183

)

(405

)

(951

)

(728

)

Non-GAAP sales and marketing expense

$

28,168

$

26,737

$

111,077

$

101,692

GAAP general and administrative expense

$

9,973

$

9,759

$

37,827

$

36,745

Adjusted to exclude the following:

Acquisition and other related expenses

(30

)

Stock-based compensation

(2,374

)

(2,372

)

(9,116

)

(8,678

)

Non-GAAP general and administrative expense

$

7,599

$

7,387

$

28,711

$

28,037

GAAP operating expense

$

63,638

$

64,448

$

260,875

$

240,454

Adjusted to exclude the following:

Acquisition and other related expenses

(30

)

Stock-based compensation

(9,583

)

(10,566

)

(37,951

)

(38,200

)

Amortization of acquired intangibles

(1,061

)

(979

)

(4,244

)

(4,164

)

Change in fair value of contingent earn-out consideration liability

(183

)

(405

)

(951

)

(728

)

Restructuring

(7,936

)

Non-GAAP operating expense

$

52,811

$

52,498

$

209,793

$

197,332

GAAP operating income

$

41,852

$

32,841

$

163,878

$

125,108

Adjusted to exclude the following:

Acquisition and other related expenses

30

Stock-based compensation

11,857

12,991

47,430

47,834

Amortization of acquired intangibles

1,061

1,116

4,518

4,712

Change in fair value of contingent earn-out consideration liability

183

405

951

728

Restructuring

7,936

Non-GAAP operating income

$

54,953

$

47,353

$

224,713

$

178,412

GAAP net income

$

40,618

$

30,668

$

147,582

$

112,818

Adjusted to exclude the following:

Acquisition and other related expenses

30

Stock-based compensation

11,857

12,991

47,430

47,834

Amortization of acquired intangibles

1,061

1,116

4,518

4,712

Change in fair value of contingent earn-out consideration liability

183

405

951

728

Restructuring

7,936

Income tax effect of non-GAAP adjustments (1)

(2,751

)

(3,048

)

(12,775

)

(11,194

)

Non-GAAP net income

$

50,968

$

42,132

$

195,642

$

154,928

Non-GAAP net income margin

43.2

%

38.0

%

41.2

%

37.0

%

Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

Basic

186,756

193,829

190,172

193,176

Diluted

201,110

212,742

205,734

213,425

Non-GAAP net income per share attributable to Class A and Class B stockholders:

Basic

$

0.27

$

0.22

$

1.03

$

0.80

Diluted

$

0.25

$

0.20

$

0.95

$

0.73

(1)

For the three months and fiscal years ended March 31, 2024 and 2023, management used an estimated annual effective non-GAAP tax rate of 21.0%.

Investor Relations Contact:

Perry Gold

[email protected]

Media Contact:

Amanda Cox

[email protected]

Source: Doximity

Categories

Business Wire Press Releases

Next Articles